Glaukos (FRA:6GJ) Notes Receivable: €0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6GJ Glaukos Corp FRA:6GJ
82 GF Score
Price €132.00
GF Value €118.07
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Glaukos Notes Receivable?

Glaukos FRA:6GJ -1.49% 82 Notes Receivable is €0.0 Mil as of Mar. 2026. GuruFocus rates FRA:6GJ with a GF Score™ of 82/100 and a GF Value™ of €118.07 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Glaukos's Notes Receivable for the quarter that ended in Mar. 2026 was €0.0 Mil.

Glaukos Notes Receivable Historical Data

* Premium members only.

The historical data trend for Glaukos's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glaukos Notes Receivable Chart

Glaukos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Glaukos Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:6GJ
82GF Score
Glaukos Corp FRA:6GJ
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glaukos Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.0 Mil mean?
Glaukos (FRA:6GJ) has a Notes Receivable of €0.0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Glaukos and its competitors.
Is Glaukos' Notes Receivable too high?
Glaukos' current Notes Receivable is €0.0 Mil. Overall, Glaukos has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' Notes Receivable compare to BIO and BRKR?
Glaukos' Notes Receivable of €0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Glaukos and its competitors. Glaukos's current Notes Receivable is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (FRA:6GJ) is currently considered Modestly Overvalued. The stock's GF Value™ is €118.07, compared to a current price of €132.00 — trading 11.8% above its estimated fair value. The current Notes Receivable is €0.0 Mil. Glaukos' overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Glaukos (FRA:6GJ), the current Notes Receivable is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glaukos (FRA:6GJ) Overvalued in 2026?

Based on GuruFocus' analysis, Glaukos stock appears to be overvalued. The current stock price of €132.00 is trading 11.8% above its estimated GF Value™ of €118.07. GuruFocus considers Glaukos to be Modestly Overvalued.

Key valuation signals for FRA:6GJ:

  • Notes Receivable: €0.0 Mil
  • GF Value™: €118.07 vs. price of €132.00 (11.8% above fair value)
  • GF Score™: 82/100 with 6 warning signs

No single metric tells the full story. See the FRA:6GJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Glaukos Business Description

Other Exchanges GKOS:USA
Address One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
82GF Score

Get the complete analysis for FRA:6GJ

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€132.00
Price
€118.07
GF Value